Dehydroeburicoic Acid from Antrodia camphorata Prevents the Diabetic and Dyslipidemic State via Modulation of Glucose Transporter 4, Peroxisome Proliferator-Activated Receptor α Expression and AMP-Activated Protein Kinase PhosphoReport as inadecuate




Dehydroeburicoic Acid from Antrodia camphorata Prevents the Diabetic and Dyslipidemic State via Modulation of Glucose Transporter 4, Peroxisome Proliferator-Activated Receptor α Expression and AMP-Activated Protein Kinase Phospho - Download this document for free, or read online. Document in PDF available to download.

1

Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung City 40402, Taiwan

2

Department of Biotechnology, Asia University, Taichung City 41354, Taiwan

3

Department of Internal Medicine, Fengyuan Hospital, Ministry of Health and Welfare, Fengyuan District, Taichung City 42055, Taiwan

4

Graduate Institute of Pharmaceutical Science and Technology, College of Health Science, Central Taiwan University of Science and Technology, No. 666 Buzih Road, Beitun District, Taichung City 40601, Taiwan



These authors contributed equally to this work.





*

Author to whom correspondence should be addressed.



Academic Editor: Ge Zhang

Abstract This study investigated the potential effects of dehydroeburicoic acid TT, a triterpenoid compound from Antrodia camphorata, in vitro and examined the effects and mechanisms of TT on glucose and lipid homeostasis in high-fat-diet HFD-fed mice. The in vitro study examined the effects of a MeOH crude extract CruE of A. camphorata and Antcin K AnK; the main constituent of fruiting body of this mushroom on membrane glucose transporter 4 GLUT4 and phospho-Akt in C2C12 myoblasts cells. The in vitro study demonstrated that treatment with CruE, AnK and TT increased the membrane levels of glucose transporter 4 GLUT4 and phospho-Akt at different concentrations. The animal experiments were performed for 12 weeks. Diabetic mice were randomly divided into six groups after 8 weeks of HFD-induction and treated with daily oral gavage doses of TT at three dose levels, fenofibrate Feno at 0.25 g-kg body weight, metformin Metf at 0.3 g-kg body weight or vehicle for another 4 weeks while on an HFD diet. HFD-fed mice exhibited increased blood glucose levels. TT treatment dramatically lowered blood glucose levels by 34.2%~43.4%, which was comparable to the antidiabetic agent-Metf 36.5%. TT-treated mice reduced the HFD-induced hyperglycemia, hypertriglyceridemia, hyperinsulinemia, hyperleptinemia, and hypercholesterolemia. Membrane levels of GLUT4 were significantly higher in CruE-treated groups in vitro. Skeletal muscle membrane levels of GLUT4 were significantly higher in TT-treated mice. These groups of mice also displayed lower mRNA levels of glucose-6-phosphatase G6 Pase, an inhibitor of hepatic glucose production. The combination of these agents produced a net hypoglycemic effect in TT-treated mice. TT treatment enhanced the expressions of hepatic and skeletal muscle AMP-activated protein kinase AMPK phosphorylation in mice. TT-treated mice exhibited enhanced expression of hepatic fatty acid oxidation enzymes, including peroxisome proliferator-activated receptor α PPARα and increased mRNA levels of carnitine palmitoyl transferase Ia CPT-1a. These mice also exhibited decreased expression levels of lipogenic fatty acid synthase FAS in liver and adipose tissue and reduced mRNA levels of hepatic adipocyte fatty acid binding protein 2 aP2 and glycerol-3-phosphate acyltransferase GPAT. These alterations resulted in a reduction in fat stores within the liver and lower triglyceride levels in blood. Our results demonstrate that TT is an excellent therapeutic approach for the treatment of type 2 diabetes and hypertriglyceridemia. View Full-Text

Keywords: dehydroeburicoic acid; Antrodia camphorata; high-fat-diet; glucose transporter 4; peroxisome proliferator-activated receptor α; fatty acid synthase dehydroeburicoic acid; Antrodia camphorata; high-fat-diet; glucose transporter 4; peroxisome proliferator-activated receptor α; fatty acid synthase





Author: Yueh-Hsiung Kuo 1,2,†, Cheng-Hsiu Lin 3,† and Chun-Ching Shih 4,*

Source: http://mdpi.com/



DOWNLOAD PDF




Related documents